InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,718.57
(
0.28%
)
US TECH 100
19,310.40
(
-0.06%
)
Dow Jones
42,124.65
(
0.15%
)
Brent Oil
75.04
(
1.76%
)
Bitcoin
63,524.67
(
0.31%
)
Post# of 92948
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

chuckanutman

Send PM Follow Ignore
Followers 43
Posts 5405
Boards Moderated 0
Alias Born 03/05/2010

chuckanutman

Re: None

Saturday, 07/04/2015 4:12:23 PM

Saturday, July 04, 2015 4:12:23 PM

Post# of 92948

stemdynasty stated something interesting about OCAT.



"Wildcards for this quarter are jv(s), a takeover, Breakthrough designation, as well as UK, Tuft's, and RNP publications (all additional layers of validation)".

"Even at this stage the company is undervalued by 2-3 Billion. I hope to see that come to fruition.
Phase 2 is the most lucrative time to make money in biotech according to hedgefunds. Will we follow history?"




Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up